Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

The BioCentury Show

The BioCentury Show artwork

Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

Sep 18, 202635 minAudio
ShareXLinkedInFacebookWhatsAppEmail

On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets. Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway. View full story: https://www.biocentury.com/article/660824 #Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials 0:00 Introduction 1:22 New Fund & Founding 10:30 Alnylam Deal 17:14 Working with Big Caps 25:54 Biotech Risk 29:13 China

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Ep. 124 - Texas Medical Center’s William McKeon on making Texas the U.S. pilot for faster trials

    Nov 13, 202633 minAudio

    Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon...

    Credit the people on this episode

  2. Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process

    Oct 30, 202634 minAudio

    On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its...

    Credit the people on this episode

  3. Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China

    Oct 21, 202630 minAudio

    Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored...

    Credit the people on this episode

  4. Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi

    Oct 17, 202637 minAudio

    Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show,...

    Credit the people on this episode

  5. Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces

    Oct 2, 202639 minAudio

    Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which...

    Credit the people on this episode